<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">39230571</PMID><DateRevised><Year>2024</Year><Month>09</Month><Day>04</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1557-3265</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2024</Year><Month>Sep</Month><Day>04</Day></PubDate></JournalIssue><Title>Clinical cancer research : an official journal of the American Association for Cancer Research</Title><ISOAbbreviation>Clin Cancer Res</ISOAbbreviation></Journal><ArticleTitle>FDA Approval Summary: Enfortumab Vedotin Plus Pembrolizumab for Locally Advanced or Metastatic Urothelial Carcinoma.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.1158/1078-0432.CCR-24-1393</ELocationID><Abstract><AbstractText>On December 15, 2023, the FDA granted traditional approval to enfortumab vedotin-ejfv plus pembrolizumab (EV + Pembro) for patients with locally advanced or metastatic urothelial carcinoma (la/mUC). Substantial evidence of effectiveness was obtained from EV-302/KEYNOTE-A39 (NCT04223856), an open-label, randomized, trial evaluating EV + Pembro versus cisplatin or carboplatin plus gemcitabine (Plat + Gem) in patients with previously untreated la/mUC. A total of 886 patients were randomized (1:1) to receive EV 1.25 mg/kg intravenously on days 1 and 8 of each 21-day cycle until disease progression or unacceptable toxicity plus pembrolizumab 200 mg intravenously on day 1 of each 21-day cycle for up to 35 cycles, or Plat + Gem for up to 6 cycles. Dual primary endpoints were progression-free survival (PFS) determined by blinded independent central review and overall survival (OS). Median PFS was 12.5 months (95% CI: 10.4, 16.6) in the EV + Pembro arm and 6.3 months (95% CI: 6.2, 6.5) in the Plat + Gem arm (HR 0.450 [95% CI: 0.377, 0.538]; p-value &lt; 0.0001). Median OS was 31.5 months (95% CI: 25.4, NE) in the EV + Pembro arm and 16.1 months (95% CI: 13.9, 18.3) in the Plat + Gem arm (HR 0.468 [95% CI: 0.376, 0.582]; p-value &lt; 0.0001). The safety profile of EV + pembrolizumab was similar to that observed in EV-103/KEYNOTE-869 in cisplatin-ineligible patients with la/mUC. This article summarizes the data and the FDA thought process supporting traditional approval of EV + pembrolizumab, as well as additional exploratory analyses conducted by FDA.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Brave</LastName><ForeName>Michael H</ForeName><Initials>MH</Initials><Identifier Source="ORCID">0000-0003-1820-2930</Identifier><AffiliationInfo><Affiliation>United States Food and Drug Administration, Silver Spring, MD, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Maguire</LastName><ForeName>William F</ForeName><Initials>WF</Initials><Identifier Source="ORCID">0000-0002-3288-8863</Identifier><AffiliationInfo><Affiliation>United States Food and Drug Administration, Silver Spring, MD, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Weinstock</LastName><ForeName>Chana</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0002-6754-9976</Identifier><AffiliationInfo><Affiliation>United States Food and Drug Administration, Silver Spring, MD, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Hui</ForeName><Initials>H</Initials><Identifier Source="ORCID">0009-0000-5436-5994</Identifier><AffiliationInfo><Affiliation>Food and Drug Administration, Silver Spring, MD, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gao</LastName><ForeName>Xin</ForeName><Initials>X</Initials><Identifier Source="ORCID">0000-0002-7383-6453</Identifier><AffiliationInfo><Affiliation>Food and Drug Administration, Silver Spring, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Fang</ForeName><Initials>F</Initials><Identifier Source="ORCID">0009-0002-2510-2647</Identifier><AffiliationInfo><Affiliation>Food and Drug Administration, Silver Spring, MD, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yu</LastName><ForeName>Jingyu</ForeName><Initials>J</Initials><Identifier Source="ORCID">0009-0006-6249-7907</Identifier><AffiliationInfo><Affiliation>United States Food and Drug Administration, Silver Spring, MD, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fu</LastName><ForeName>Wentao</ForeName><Initials>W</Initials><Identifier Source="ORCID">0009-0003-5259-8307</Identifier><AffiliationInfo><Affiliation>United States Food and Drug Administration, Silver Spring, MD, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhao</LastName><ForeName>Hong</ForeName><Initials>H</Initials><Identifier Source="ORCID">0000-0003-1661-2506</Identifier><AffiliationInfo><Affiliation>United States Food and Drug Administration, Silver Spring, Maryland, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pierce</LastName><ForeName>William F</ForeName><Initials>WF</Initials><Identifier Source="ORCID">0000-0002-3411-7720</Identifier><AffiliationInfo><Affiliation>Food and Drug Administration, Silver Spring, Maryland, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chang</LastName><ForeName>Elaine</ForeName><Initials>E</Initials><Identifier Source="ORCID">0000-0001-6255-2853</Identifier><AffiliationInfo><Affiliation>United States Food and Drug Administration, Silver Spring, MD, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dinin</LastName><ForeName>Jeannette</ForeName><Initials>J</Initials><Identifier Source="ORCID">0009-0006-2605-1000</Identifier><AffiliationInfo><Affiliation>United States Food and Drug Administration, White Oak, MD, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fiero</LastName><ForeName>Mallorie H</ForeName><Initials>MH</Initials><Identifier Source="ORCID">0000-0001-5536-116X</Identifier><AffiliationInfo><Affiliation>United States Food and Drug Administration, Silver Spring, MD, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rahman</LastName><ForeName>Nam Atiqur</ForeName><Initials>NA</Initials><Identifier Source="ORCID">0009-0001-0002-7006</Identifier><AffiliationInfo><Affiliation>Food and Drug Administration, Silver Spring, MD, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tang</LastName><ForeName>Shenghui</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-0437-665X</Identifier><AffiliationInfo><Affiliation>United States Food and Drug Administration, Silver Spring, MD, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pazdur</LastName><ForeName>Richard</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0002-4771-9923</Identifier><AffiliationInfo><Affiliation>United States Food and Drug Administration, Silver Spring, MD, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kluetz</LastName><ForeName>Paul G</ForeName><Initials>PG</Initials><Identifier Source="ORCID">0000-0002-9796-4791</Identifier><AffiliationInfo><Affiliation>Food and Drug Administration, Silver Spring, MD, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Amiri-Kordestani</LastName><ForeName>Laleh</ForeName><Initials>L</Initials><Identifier Source="ORCID">0000-0002-0056-5437</Identifier><AffiliationInfo><Affiliation>Food and Drug Administration Center for Drug Evaluation and Research, Silver Spring, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Suzman</LastName><ForeName>Daniel L</ForeName><Initials>DL</Initials><Identifier Source="ORCID">0000-0002-1702-6114</Identifier><AffiliationInfo><Affiliation>United States Food and Drug Administration, Silver Spring, MD, United States.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>04</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Clin Cancer Res</MedlineTA><NlmUniqueID>9502500</NlmUniqueID><ISSNLinking>1078-0432</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>5</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>7</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>9</Month><Day>4</Day><Hour>12</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>9</Month><Day>4</Day><Hour>12</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>9</Month><Day>4</Day><Hour>10</Hour><Minute>53</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39230571</ArticleId><ArticleId IdType="doi">10.1158/1078-0432.CCR-24-1393</ArticleId><ArticleId IdType="pii">747796</ArticleId></ArticleIdList></PubmedData></PubmedArticle>